Abstract
Minocycline is an antibiotic with anti-inflammatory and antiapoptotic properties that prolongs survival in a transgenic Huntington disease (HD) mouse model. In a double-blind, randomized, placebo-controlled study of minocycline in 60 HD patients, the authors determined that over 8 weeks, minocycline at 100 and 200 mg/day was well tolerated and safe in HD patients. Tolerability and adverse event frequency were similar between treatment and placebo groups.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Apoptosis / drug effects
-
Caspase 3
-
Caspase Inhibitors
-
Cysteine Proteinase Inhibitors / administration & dosage
-
Cysteine Proteinase Inhibitors / adverse effects
-
Cysteine Proteinase Inhibitors / therapeutic use*
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Female
-
Gastrointestinal Diseases / chemically induced
-
Humans
-
Huntington Disease / drug therapy*
-
Male
-
Middle Aged
-
Minocycline / administration & dosage
-
Minocycline / adverse effects
-
Minocycline / therapeutic use*
-
Patient Dropouts
-
Treatment Failure
-
Treatment Outcome
Substances
-
Caspase Inhibitors
-
Cysteine Proteinase Inhibitors
-
CASP3 protein, human
-
Casp3 protein, mouse
-
Caspase 3
-
Minocycline